Semma Therapeutics

Vertex buys developer of preclinical cell therapy for Type 1 diabetes for $950M

The Boston-based company said it would acquire Semma Therapeutics, which is developing a stem cell-derived therapy and device for the disease. Preclinical data were announced in July, and clinical trials are planned for 2020.

By Alaric DeArment

BioPharma, Startups

Massachusetts accounted for more than one-third of biopharma VC funding last year, report shows

The report also showed 1H18 VC funding already nearly equaled investment in 2017. That's consistent with Silicon Valley Bank's findings on Series A rounds last month.

By Alaric DeArment

Vertex buys developer of preclinical cell therapy for Type 1 diabetes for $950M

Massachusetts accounted for more than one-third of biopharma VC funding last year, report shows

Market Trends to Watch for Health Systems and Their Specialty Pharmacies